FinnCap Reiterates “Corporate” Rating for Proteome Sciences plc (LON:PRM)
Proteome Sciences plc (LON:PRM)‘s stock had its “corporate” rating reaffirmed by equities researchers at FinnCap in a research note issued to investors on Friday. They presently have a GBX 12 ($0.15) price target on the stock. FinnCap’s price target indicates a potential upside of 174.29% from the company’s previous close.
Proteome Sciences plc (LON PRM) traded up 2.339% during mid-day trading on Friday, hitting GBX 4.375. 3,354,722 shares of the stock were exchanged. The stock’s market cap is GBX 10.72 million. The company has a 50 day moving average price of GBX 4.89 and a 200 day moving average price of GBX 4.83. Proteome Sciences plc has a 52 week low of GBX 3.50 and a 52 week high of GBX 20.25.
In related news, insider Martin Diggle bought 100,000 shares of the firm’s stock in a transaction on Thursday, April 27th. The stock was purchased at an average price of GBX 5 ($0.06) per share, with a total value of £5,000 ($6,359.70). Insiders have acquired 498,671 shares of company stock valued at $2,493,355 in the last ninety days.
Proteome Sciences plc Company Profile
Proteome Sciences plc is a protein biomarker company specializing in proteomics and peptidomics services and applications, and mass spectrometry (MS) protein analysis. The Company is engaged in biomarker research and development in applied proteomics and workflows using its techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications.
Receive News & Ratings for Proteome Sciences plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences plc and related companies with MarketBeat.com's FREE daily email newsletter.